LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating <em>MDR1</em> expression

Hu,Yunfeng; Cui,Jie; Jin,Lei; Su,Yani; Zhang,Xiaozhi

doi:10.3892/or.2021.7955

LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating MDR1 expression

Authors:
- Yunfeng Hu
- Jie Cui
- Lei Jin
- Yani Su
- Xiaozhi Zhang
View Affiliations

Affiliations: Department of Radiotherapy, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Oncology, The First Affiliated Hospital, Xi'an Medical University, Xi’an, Shaanxi 710077, P.R. China, School of General Medicine, Xi'an Medical University, Xi’an, Shaanxi 710077, P.R. China, Department of Oncology, Yanan University Affiliated Hospital, Yanan University, Yan'an, Shaanxi 716000, P.R. China
Published online on: January 28, 2021 https://doi.org/10.3892/or.2021.7955
Article Number: 4

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of multidrug resistance is the major obstacle to successful lung cancer chemotherapy. Cancer cells gain resistance through increased levels of P‑glycoprotein (P‑gp), which is encoded by the multidrug resistance‑associated protein 1 (MDR1) gene. Leucine‑rich PPR motif‑containing protein (LRPPRC), a member of the PPR family, has been verified to regulate the transcription of MDR1. This regulation is influenced by the methylation status of the GC ‑100 box in the MDR1 promoter. The present study aimed to investigate the effect of LRPPRC on cisplatin (DDP) resistance in lung cancer cells and explore the underlying mechanism. DDP‑resistant non‑small cell lung cancer cell lines (A549/DDP, H1299/DDP) were generated. The expression levels of LRPPRC and P‑gp/MDR1, investigated by qPCR and western blot analysis, were increased in the A549/DDP and H1299/DDP cells compared with that in the parental cells. LRPPRC silencing with shRNA increased DDP sensitivity in vitro and in vivo. LRPPRC silencing inhibited the level of LRPPRC binding with the MDR1 promoter, investigated by chromatin immunoprecipitation‑qPCR, and the corresponding MDR1 expression. Demethylation treatment rescued the decrease in the level of LRPPRC binding with MDR1 and the corresponding expression of MDR1 and the increase in DDP sensitivity due to LRPPRC silencing. Our study suggests that LRPPRC contributes to DDP resistance in lung cancer cells by regulating MDR1 transcription. Thus, LRPPRC may serve as a potential molecular target for chemo‑resistance reversal in lung cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Tian R, Zhang C, Xiong F and Chen H: PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer. Front Biosci (Landmark Ed). 25:948–960. 2020. View Article : Google Scholar : PubMed/NCBI
3	Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF and Xie D: CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Cell Death Dis. 10:992019. View Article : Google Scholar : PubMed/NCBI
4	Vasiliou V, Vasiliou K and Nebert DW: Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 3:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
5	Pérez-Tomás R: Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
6	Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 370:153–164. 2016. View Article : Google Scholar : PubMed/NCBI
7	Manna S: An overview of pentatricopeptide repeat proteins and their applications. Biochimie. 113:93–99. 2015. View Article : Google Scholar : PubMed/NCBI
8	Cui J, Wang L, Ren X, Zhang Y and Zhang H: LRPPRC: A multifunctional protein involved in energy metabolism and human disease. Front Physiol. 10:5952019. View Article : Google Scholar : PubMed/NCBI
9	Tian T, Ikeda J, Wang Y, Mamat S, Luo W, Aozasa K and Morii E: Role of leucine-rich pentatricopeptide repeat motif-containing protein (lrpprc) for anti-apoptosis and tumourigenesis in cancers. Eur J Cancer. 48:2462–2473. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhang HY, Ma YD, Zhang Y, Cui J and Wang ZM: Elevated Levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer. J Clin Pathol. 70:383–389. 2017. View Article : Google Scholar : PubMed/NCBI
11	Corrêa S, Binato R, Du Rocher B, Ferreira G, Cappelletti P, Soares-Lima S, Pinto LF, Mencalha A and Abdelhay E: ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC −100 box in its promoter. Epigenetics. 9:1172–1183. 2014. View Article : Google Scholar : PubMed/NCBI
12	Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J and Baggetto LG: New invMED1 element cis-activates human multidrug-related ABCB1 and MVP genes, involving the LRP130 protein. Nucleic Acids Res. 32:3864–3876. 2004. View Article : Google Scholar : PubMed/NCBI
13	Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H and Miyamoto S: Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics. 13:312016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Corrêa S, Pizzatti L, Du Rocher B, Mencalha A, Pinto D and Abdelhay E: A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in lucena cell line. Proteome Sci. 10:232012. View Article : Google Scholar : PubMed/NCBI
16	Corrêa S, Pizzatti L, Du Rocher B and Abdelhay E: Comparative proteomic study of multidrug resistance in chronic myeloid leukemia. Eur J Cancer Supplements. 8:2042010. View Article : Google Scholar
17	Li X, Lv L, Zheng J, Zhou J, Liu B, Chen H, Liang C, Wang R, Su L, Li X and Fan D: The significance of LRPPRC overexpression in gastric cancer. Med Oncol. 31:8182014. View Article : Google Scholar : PubMed/NCBI
18	Li X, Zhou J and Li X: Reversal of multidrug resistance in gastric cancer cells by LRPPRC downregulation. J Digest Dis. 15:842014.
19	Michaud M, Barakat S, Magnard S, Rigal D and Baggetto LG: Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells. Int J Oncol. 38:169–178. 2011.PubMed/NCBI
20	Choi HS, Kim YK and Yun PY: Upregulation of MDR- and EMT-related molecules in cisplatin-resistant human oral squamous cell carcinoma cell lines. Int J Mol Sci. 20:E30342019. View Article : Google Scholar : PubMed/NCBI
21	Januchowski R, Sterzyńska K, Zaorska K, Sosińska P, Klejewski A, Brązert M, Nowicki M and Zabel M: Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 9:652016. View Article : Google Scholar : PubMed/NCBI